Client First Capital LLC Makes New Investment in Eli Lilly and Company $LLY

Client First Capital LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 690 shares of the company’s stock, valued at approximately $538,000. Eli Lilly and Company accounts for about 0.3% of Client First Capital LLC’s investment portfolio, making the stock its 17th biggest holding.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Lazard Freres Gestion S.A.S. increased its holdings in Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after purchasing an additional 41,222 shares during the period. Precedent Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after buying an additional 39 shares during the period. Capital Advisors Inc. OK grew its position in shares of Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after buying an additional 429 shares during the last quarter. Family CFO Inc purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $54,000. Finally, Duquesne Family Office LLC increased its stake in shares of Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 3.0%

NYSE:LLY opened at $1,018.28 on Thursday. The firm’s 50-day moving average price is $815.33 and its 200-day moving average price is $778.16. The company has a market capitalization of $962.67 billion, a PE ratio of 66.55, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,022.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period last year, the company posted $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. HSBC upped their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, The Goldman Sachs Group raised their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $981.89.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.